For greater potential upside, consider earlier-stage smid-cap biotech names. Small- and midcap biotech stocks are riskier, but have been hardest hit in the sector's decline. "Smid-cap biotech looks ...

In today’s heightened enforcement environment, compliance auditing isn’t just a best practice—it’s a necessity. Federal and ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren’t in bad shape either. So, is it the right time to bet on ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

At least three new startups have already been launched out of the fund: U.K.-based Forth Therapeutics, French biotech ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29. ...

On Wednesday, H.C. Wainwright reaffirmed a Buy rating and a price target of $54.00 on Biohaven Pharmaceutical (TADAWUL:2070) ...

Pre-Open Stock Movers: Biohaven Pharmaceutical (NYSE:BHVN) 71% HIGHER; Pfizer Inc. (NYSE:PFE) and Biohaven Pharmaceutical... After-Hours Stock Movers 05/09: AMC, RingCentral Gain on Earning ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) diving into the opportunity to make effective and targeted ...